Meister Keith A. sold $5.9M of ILMN (indirect holdings)

Meister Keith A. sold 375,941 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $226.74 ($224.72–$231.23, $85.24M total) across 13 trades over 2026-08-25 to 2026-08-27.

Illumina (ILMN) secured a new $1.00 billion revolving credit facility, replacing its 2023 agreement. The facility offers variable-rate borrowing and covenant limits, with no amounts drawn initially. This enhances liquidity and financial flexibility amid stronger revenue and earnings guidance. The company's focus remains on clinical sequencing, with risks including competition, China exposure, and research funding. Analysts' revenue growth expectations vary, with some projecting 5.2% annual growt

Illumina (ILMN) stock has risen 82% in six months, closing at $223.22 on August 24. The surge follows three quarters of raised guidance due to strong clinical sequencing demand. Analysts' average price target is $199, 11% below the current price. TIKR's model values the stock at $259 by late 2030, implying a 16% total return. Potential S&P 500 inclusion adds speculative momentum.

Illumina (ILMN) has secured a new $1 billion unsecured revolving credit facility, replacing its prior agreement. The facility offers updated covenants and increased flexibility for future financing. According to the company, it will serve as a liquidity backstop and support capital structure decisions. The credit line is expected to fund working capital, equipment, and potential projects, but may impact debt-to-equity metrics if not matched by earnings growth.

Moderna's [MRNA] personalized mRNA cancer vaccine, intismeran, met Phase 3 trial endpoints, boosting its shares and Merck's [MRK] as it's administered with Keytruda. Illumina [ILMN] and Pacific Biosciences [PACB] also rose due to their sequencing technology's role. BioNTech [BNTX] gained as investors reassessed mRNA cancer therapies. Moderna reported Q2 revenue of $145M and a net loss of $782M, while Illumina reported Q2 revenue of $1.16B and raised 2026 guidance. BioNTech reported Q2 revenue of

MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.